Ning Liao

462 total citations
23 papers, 277 citations indexed

About

Ning Liao is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ning Liao has authored 23 papers receiving a total of 277 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 11 papers in Cancer Research and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ning Liao's work include HER2/EGFR in Cancer Research (13 papers), Breast Cancer Treatment Studies (9 papers) and Cancer Treatment and Pharmacology (6 papers). Ning Liao is often cited by papers focused on HER2/EGFR in Cancer Research (13 papers), Breast Cancer Treatment Studies (9 papers) and Cancer Treatment and Pharmacology (6 papers). Ning Liao collaborates with scholars based in China, United States and Taiwan. Ning Liao's co-authors include Guochun Zhang, Bo Chen, Li Cao, Zefei Jiang, Jiali Lin, Minghan Jia, Yulei Wang, Chongyang Ren, Xiaohong Chen and Cheukfai Li and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Ning Liao

21 papers receiving 274 citations

Peers

Countries citing papers authored by Ning Liao

Since Specialization

Citations

This map shows the geographic impact of Ning Liao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ning Liao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ning Liao more than expected).

Fields of papers citing papers by Ning Liao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ning Liao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ning Liao. The network helps show where Ning Liao may publish in the future.

Co-authorship network of co-authors of Ning Liao

This figure shows the co-authorship network connecting the top 25 collaborators of Ning Liao. A scholar is included among the top collaborators of Ning Liao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ning Liao. Ning Liao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association between metabolic dysfunction-associated steatotic liver disease and insulin resistance in individuals with normoglycemia 2025 ·Medicine ·Ning Liao, Chunyi Wang, (unknown), (unknown), Wen‐Yuan Lin, Tsung‐Po Chen	1
2	A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with PIK3CA-mutated, HR+/HER2- advanced breast cancer. 2024 ·Journal of Clinical Oncology ·Jiong Wu, Jian Zhang, Man Li, Li Cai, Tao Sun, Quchang Ouyang, Yanchun Meng, Yehui Shi, Chuan Wang, Qiang Liu, Yongkui Lu, Yongmei Yin, Qianjun Chen, Lilin Chen, Haitao Wang, Jiuwei Cui, Ning Liao, Shubin Wang, Yi Tu, Min Yan	1
3	An in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses 2024 ·Nature Communications ·(unknown), (unknown), (unknown), Yuanyuan Wu, Jiale Liu, Haocheng Wang, Yuting Luo, Jie Zhan, Ning Liao, Yanbin Cai	29
4	High expression level of the FTH1 gene is associated with poor prognosis in children with non-M3 acute myeloid leukemia 2023 ·Frontiers in Oncology ·Junlin Zhang, Liying Liu, (unknown), Xiaojing Wu, (unknown), Hongying Wei, Ning Liao, Yunyan He	10
5	Heterogenous and Low Expression of HER2 in Breast Cancer Overcome by DS-8201a in a Heavily Treated Patient: Case Report and Review of the Literature 2022 ·Clinical Medicine Insights Oncology ·Cheukfai Li, Chongyang Ren, Lingzhu Wen, Xiaohong Chen, Bo Chen, Guochun Zhang, Yulei Wang, Kai Li, Li Cao, Minghan Jia, Hsiaopei Mok, Jianguo Lai, Weikai Xiao, Xuerui Li, Ning Liao	1
6	Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status 2022 ·BMC Medicine ·Guochun Zhang, Chongyang Ren, Cheukfai Li, Yulei Wang, Bo Chen, Lingzhu Wen, Minghan Jia, Kai Li, Hsiaopei Mok, Li Cao, Xiaohong Chen, Jiali Lin, Guangnan Wei, Yingzhi Li, Yuchen Zhang, Charles M. Balch, Ning Liao	90
7	Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study 2021 ·Japanese Journal of Clinical Oncology ·Zhimin Shao, Ling‐Ming Tseng, Chiun‐Sheng Huang, Da Pang, Youngsen Yang, Wei Li, Ning Liao, Cuizhi Geng, Qingyuan Zhang, Binghe Xu, Donggeng Liu, Ava Kwong, (unknown)	2
8	Integrated analysis of cell cycle-related genes in HR+/HER2− breast cancer 2021 ·Breast Cancer ·Jianguo Lai, Bo Chen, Yingzi Li, Xiaoyi Lin, Min Li, Jing Liu, Ning Liao	2
9	Analysis of Prognostic Factors Affecting the Brain Metastases Free Survival and Survival After Brain Metastases in Breast Cancer 2020 ·Frontiers in Oncology ·Weikai Xiao, Xuerui Li, Anli Yang, Bo Chen, Shaoquan Zheng, Guochun Zhang, (unknown), Ning Liao	9
10	Abstract P5-08-22: Associations between MYC alterations and clinical pathological characteristics in Chinese patients and TCGA cohort 2020 ·Cancer Research ·Li Cao, Guochun Zhang, Yulei Wang, Bo Chen, Chongyang Ren, Lingzhu Wen, Liping Guo, Kai Li, Minghan Jia, Ning Liao	1
11	PARPBP is a prognostic marker and confers anthracycline resistance to breast cancer 2020 ·Therapeutic Advances in Medical Oncology ·Bo Chen, Jianguo Lai, Danian Dai, Rong Chen, Ning Liao, Guanfeng Gao, Hailin Tang	9
12	Abstract P6-17-17: Pertuzumab, trastuzumab, and docetaxel for HER2-positive early or locally advanced breast cancer in the neoadjuvant setting: Efficacy and safety analysis of a randomized phase III study in Asian patients (PEONY) 2019 ·Cancer Research ·Zhimin Shao, Da Pang, Hongjian Yang, Wei Li, Shanshan Wang, Shengjie Cui, Ning Liao, (unknown), Chao Wang, Yeun‐Chung Chang, Hao Wang, (unknown), Jiang Zhang, J Li, Juan Zhou, Betsy Althaus, Yan‐Ping Mao, Jennifer Eng‐Wong	3
13	Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China 2018 ·Medicine ·Junjie Li, Zhimin Shao, Binghe Xu, Zefei Jiang, Shude Cui, Jin Zhang, Ning Liao, Jun Jiang, Yongsheng Wang, Quchang Ouyang, (unknown)	13
14	Palbociclib plus letrozole as first-line treatment for ER-positive and HER2-negative advanced breast cancer in Chinese women: a phase 1 study 2017 ·The Lancet Oncology ·Huiping Li, Qingyuan Zhang, (unknown), Shusen Wang, Ning Liao, Peng Shen, Bin Shao, Wenhui Zhao, Wan Sun, Ping Yan, Diane Wang, (unknown), Carlos Linn, Haihong Shi, Melissa O’Gorman, Binghe Xu	4
15	A phase II trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer 2016 ·Breast Cancer Research and Treatment ·Teng Zhu, (unknown), (unknown), (unknown), (unknown), Jian Zu, (unknown), (unknown), Ning Liao, Kun Wang	15
16	Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study 2016 ·Oncotarget ·Binghe Xu, Xichun Hu, Hong Zheng, Xiaojia Wang, Qingyuan Zhang, Shude Cui, Donggeng Liu, Ning Liao, Rongcheng Luo, Qiang Sun, Shiying Yu	11
17	Outcomes of re-treatment with first-line trastuzumab plus taxane in patients (pts) with metastatic breast cancer (mBC) who relapsed after (neo)adjuvant trastuzumab: A prospective multicenter study. 2016 ·Journal of Clinical Oncology ·Binghe Xu, Xichun Hu, Hong Zheng, Xiaojia Wang, Qingyuan Zhang, Shude Cui, Donggeng Liu, Ning Liao, Rongcheng Luo, Qiang Sun, Shiying Yu	1
18	Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial 2013 ·Annals of Oncology ·Zefei Jiang, Massimo Cristofanilli, Zhi‐Ming Shao, Zhongsheng Tong, (unknown), (unknown), Ning Liao, Xianglin Hu, Yi Liu, (unknown), Le Zeng, (unknown)	50
19	Tau expression correlated with breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy 2012 ·Tumor Biology ·Kun Wang, (unknown), Ning Liao, Guochun Zhang, Yan‐Hui Liu, Fangping Xu, Jian Zu, Xuerui Li, Yi‐Long Wu	20
20	[A meta-analysis of neoadjuvant chemotherapy combined with trastuzumab for HER2-positive breast cancers]. 2009 ·PubMed ·Ning Liao, Guochun Zhang, Xuerui Li, (unknown), Kun Wang	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact